Camrelizumab

Last updated

Camrelizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target PD1
Clinical data
Other namesSHR-1210
ATC code
Identifiers
CAS Number
DrugBank
UNII

Camrelizumab (INN; [1] development code SHR-1210) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. [2] PD-1 is programmed cell death protein 1.

The drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019, camrelizumab is undergoing Phase II/III trials.

In China, in May 2025 camrelizumab was conditionally approved for use in combination with famitinib for the treatment of recurrent or metastatic cervical cancer in patients who have failed prior platinum-based chemotherapy and have not received prior bevacizumab. [3]

References

  1. ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
  2. ↑ Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. (June 2019). "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma". Journal of Clinical Oncology. 37 (17): 1479–1489. doi: 10.1200/JCO.18.02151 . PMID   31039052. S2CID   141482897.{{cite journal}}: CS1 maint: overridden setting (link)
  3. ↑ Keam SJ (2025). "Famitinib: First Approval". Drugs. 85 (12): 1613–1620. doi:10.1007/s40265-025-02238-1. PMID   40996477.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.